

# **Hypoxyprobe™-1**

**[Pimonidazole Hydrochloride]**

**[CAS# 70132-50-2]**

**An Investigational New Drug for the detection of tissue hypoxia**

***Material Safety Data Sheet***

**Updated 2019**

---

**Material Safety Data Sheet**

Date Printed: 01/30/2001

Date Updated: 01/10/2019

Version 3.0

---

**Section 1 - Product and Company Information**

---

**Product Name** Pimonidazole Hydrochloride  
**Brand Name** Hypoxyprobe™-1  
**Company** Hypoxyprobe, Inc (HPI)  
**Street Address** 121 Middlesex Turnpike  
**City, State, Zip, Country** Burlington, MA 01803, USA  
**Technical Phone:** 781-272-6888  
**Fax** 781-272-9288  
**e-mail** [tlee@natural-pharma.com](mailto:tlee@natural-pharma.com)

---

**Section 2 – Composition/Information on Ingredients**

---

**Substance Name** Pimonidazole hydrochloride  
**CAS #** 70132-50-2  
**SARA 313 listed:** No  
**Formula** C<sub>11</sub>H<sub>19</sub>N<sub>4</sub>O<sub>3</sub>Cl

**Synonyms** 1-[(2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole hydrochloride; Ro 03-8799 hydrochloride salt; Hypoxyprobe™-1.

---

**Section 3 – Hazards Identification**

---

**Emergency Overview**

Toxic (USA) Harmful (EU).  
Harmful if swallowed in quantities exceeding 0.5 gm/m2.  
For additional information on toxicity, please refer to Section 11

---

**Section 4 – First Aid Measures**

---

**Oral Exposure**

If swallowed, wash out mouth with water provided person is conscious. Call a physician.

**Inhalation Exposure**

If inhaled, remove to fresh air. If not breathing give artificial respiration. If breathing is difficult, give oxygen.

**Dermal Exposure**

In case of contact, immediately wash skin with soap and copious amounts of water.

**Eye Exposure**

In case of contact, immediately flush eyes with copious amounts of water for at least 15 minutes.

**Section 5 – Fire Fighting Measures**

**Autoignition Temp:** N/A

**Flammability:** N/A

**Extinguishing Media**

**Suitable:** Water spray. Carbon dioxide, dry chemical powder, or appropriate foam.

**Firefighting**

**Protective Equipment:** Wear protective clothing to prevent contact with body.

**Exposure Hazard(s)**

**Material:** **Low toxicity.** Toxicity develops at dosages that exceed 0.5 gm/m2 administered daily for 20 days.

**Section 6 – Accident Release Measures**

**Procedure(s) of Personal Precaution(s)**

Wear gloves.

**Methods for Cleaning Up**

Sweep up, place in a bag and hold for waste disposal. Avoid raising dust. Ventilate area and wash spill site after material pickup is complete.

**Section 7 – Handling and Storage**

**Handling: User Exposure**

Avoid unnecessary contact. Do not get in eyes, on skin, on clothing.

**Storage**

Keep tightly closed. Store in a cool dry place under conditions of subdued light.

**Section 8 – Exposure Controls/PPE**

**Engineering Controls:** Safety shower and eye bath.

**Personal Protective Equipment**

**Hand:** Gloves.  
**Eye:** Chemical safety goggles.

**General Hygiene Measures:** Wash after handling.  
 Wash contaminated clothing before reuse.

**Section 9 – Physical/Chemical Properties**

**Appearance**

**Color:** Light beige  
**Form:** Fine crystals

**Molecular Weight:** 290.17 AMU

**Section 9 – Physical/Chemical Properties (cont'd)**

<u>Property</u>	<u>Value</u>
pH	N/A
BP/BP Range	N/A
MP/MP Range	N/A
Freezing Point	N/A
Vapor Pressure	N/A
Vapor Density	N/A
Saturated Vapor Conc.	N/A
SG/Density	N/A
Bulk Density	N/A
Odor Threshold	N/A
Volatile %	N/A
VOC Content	N/A
Water Content	N/A
Solvent Content	N/A
Evaporation Rate	N/A
Viscosity	N/A
Partition Coefficient	8.5 for free base in octanol/water system.
Decomposition Temp.	N/A
Flash Point °F	N/A
Flash Point °C	N/A
Explosion Limits	N/A
Autoignition Temp	N/A
Solubility	400 millimolar in aqueous solution

**Section 10 – Stability and Reactivity**

**Stability:** Highly stable as solid or aqueous solution when stored at 4°C in the absence of light.

**Materials to Avoid:** Strong oxidizing agents: strong illumination

**Hazardous Deat Decomposition Products:** Carbon monoxide, Carbon dioxide, Nitrogen oxides.

---

**Section 11 – Toxicological Information**

---

**Route of Exposure**

**Multiple Routes:** Harmful if swallowed, inhaled, or absorbed through skin in high dosages

**Toxicity Data and Signs and Symptoms of Exposure****Mice**

LD50/7days in mice: 728 mg/kg (Walton et al, Br. J. Cancer 59: 667-675, 1989).

LD50/2days in mice: 680 mg/kg (Stone et al, Int. J. Radiat. Oncol. Biol. Phys. 12:1097-1100, 1986).

**Non-human primates**

In a 28-day toxicity study, intravenous pimonidazole hydrochloride doses of 50, 120 and 300 mg/kg/day were administered in three study groups of cynomolgus monkeys (long-tailed macaque; *Macaca fascicularis*) for 10 days. At this time, liver function tests revealed liver damage in some of the monkeys that were receiving 300mg/kg/day. One monkey in this group died and post mortem histological investigation revealed acute liver damage. The daily dosage of pimonidazole hydrochloride was decreased from 50, 120 and 300 mg/kg/day to 33, 80 and 200 mg/kg/day, respectively, in the three study groups. Liver function tests returned to control levels in the ensuing 18 days of daily 200 mg/kg/day dosage in the monkeys that had initially received 300 mg/kg/day. There was no functional or histological evidence of liver damage at the end of 28 days for monkeys in any of the study groups. There was no evidence of hepatotoxicity in rats dosed with pimonidazole hydrochloride in a manner similar to that used for monkeys. In monkeys, there was no adverse effect on spermatogenesis in any of the study groups but some salivation was noted in monkeys receiving 80 and 200 mg/kg/day for 28 days. Muscle tremor and vomiting were observed occasionally in the 200mg/kg/day group of monkeys. Some locomotor disturbances lasting a few minutes to several hours were seen in rats receiving 200 mg/kg/day.

**Humans**

The single dose of 0.5 gm/m<sup>2</sup> of pimonidazole hydrochloride used for tumor hypoxia measurement in humans is equivalent to approximately 13 mg/kg and, therefore, far below the dose of 300 mg/kg/day for 10 days that appears to be near the threshold for liver damage in primates. Although pimonidazole hydrochloride, like many 2-nitroimidazole drugs, is toxic to hypoxic cells, pimonidazole hydrochloride is not toxic to hypoxic cells at the concentrations used for hypoxia marking in animals or humans.

When injected intravenously in humans, doses that exceed 0.75 gram /meter squared can produce diarrhea, vomiting, skin rash, sweating, disorientation and feelings of malaise and heat. Ingestion of total doses that exceed 1.0 gram/meter squared (typically 0.75 – 1.0 gram total) are likely to have similar central nervous toxicities. Total doses equal to or greater than 5.0 grams can induce transient coma but no long term toxic sequelae are expected even at this high dose.

**Section 12 – Ecological Information**

Not applicable.

**Section 13 – Disposal Considerations**

**Appropriate Method of Disposal of Substance or Preparation**

Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. Observe all federal, state, and local environmental regulations.

**Section 14 – Transport Information**

**DOT**

**Proper Shipping Name:** Organic, n.o.s.

**Packing Group:** Packing Group III

**Section 15 – Regulatory Information**

**US Classification and Label Text**

**Indication of Danger**

Toxic (USA) Harmful (EU).

**Risk Statements**

Harmful if swallowed in large quantity.

**Safety Statements**

In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.  
Wear suitable protective clothing.

**United States Regulatory Information**

**SARA 313 Listed:** No

**Section 16 – Other Information**

**Warranty**

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. NPI Inc. shall not be held liable for any damage resulting from handling or from contact with the above product.